Neurocrine's Bold Move: Acquisition of Soleno Therapeutics Finalized

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Neurocrine Biosciences, Inc. has officially completed its acquisition of Soleno Therapeutics, Inc., marking a significant advancement in its commitment to rare diseases, particularly in endocrinology. This acquisition strengthens Neurocrine’s existing portfolio by adding VYKAT™ XR, a groundbreaking treatment designed specifically for hyperphagia associated with Prader-Willi syndrome (PWS).

What is Prader-Willi Syndrome?

Prader-Willi syndrome is a rare genetic neurodevelopmental disorder occurring due to an abnormality in gene expression on chromosome 15. Affecting approximately 10,000 individuals across the United States, PWS significantly impacts neurological, behavioral, and metabolic functions. One of its most troubling features is hyperphagia—a chronic condition characterized by excessive hunger and compulsive food-seeking behavior. This can lead to severe health complications, diminishing both quality of life and life expectancy for those affected.

Acquisition Details

The acquisition, announced on April 6, 2026, involves a total equity value of $2.9 billion, and it represents a crucial step in Neurocrine's strategy towards expanding its repertoire of treatments for underserved conditions. The tender offer for Soleno’s outstanding common stock was set at $53.00 per share. As of the expiration of the tender offer on May 15, 2026, most of Soleno's shares were validly tendered, leading to a successful transaction that concluded on May 18, 2026.

Implications for Patients and Families

Kyle W. Gano, Ph.D., the CEO of Neurocrine Biosciences, expressed excitement about the acquisition, emphasizing its importance in the mission to provide effective treatments for those dealing with significant health challenges. Gano remarked, "We welcome our Soleno colleagues to Neurocrine and share their deep commitment to the Prader-Willi syndrome community."

With VYKAT XR now part of Neurocrine's lineup alongside existing treatments such as INGREZZA® and CRENESSITY®, the company is poised to leverage its strong market experience to improve the management of PWS. VYKAT XR was approved by the FDA on March 26, 2025, and is now commercially available to American patients.

The Future of Neurocrine and PWS Treatment

Neurocrine’s acquisition of Soleno Therapeutics is not just a merger of two companies but a union of shared goals to create life-changing therapies. With VYKAT XR, Healthcare professionals now have access to the first and only approved treatment for managing hyperphagia in patients aged 4 years and older with PWS, giving hope to families navigating this difficult condition.

The management of PWS presents unique challenges, but with the addition of VYKAT XR to Neurocrine’s portfolio, there is a solidified commitment to tackle these hurdles through innovative solutions. As the company integrates Soleno's operations, the focus will remain on ensuring that more patients and their families can benefit from these essential treatments.

Conclusion

Neurocrine Biosciences' acquisition of Soleno Therapeutics is a pivotal moment for both companies and those affected by Prader-Willi syndrome. As this new chapter unfolds, patients and families can expect enhanced support and new treatment options that reflect the ongoing dedication of Neurocrine to alleviate suffering for those with significant unmet needs.